Chimera Research Group
  • About – Who We Are
    • Our Team
    • Subscription Service
    • Video Tour
    • Contact Us
  • Blog – Free Reports
  • Tools – Premium Access
    • Biotech M&A – 2025 Deals
    • Biotech M&A – 2024 Deals
    • Biotech M&A – 2023 Deals
    • Biotech M&A – 2022 Deals
    • Biotech M&A – 2021 Deals
    • Biotech M&A – 2020 Deals
    • Biotech M&A – 2019 Deals
    • Biotech M&A – 2018 Deals
    • Clinical Holds – 2022
    • Direct Email
    • Real-Time Tweets
    • Real-Time Email Alerts
    • Team Positions
    • FAQ
  • All Reports – Premium Research
    • Daily Update
    • Research Reports
    • Charts & TA
    • Trade Reports
    • Tutorials
  • Forum – Exchange Insight
  • About – Who We Are
    • Our Team
    • Subscription Service
    • Video Tour
    • Contact Us
  • Blog – Free Reports
  • Tools – Premium Access
    • Biotech M&A – 2025 Deals
    • Biotech M&A – 2024 Deals
    • Biotech M&A – 2023 Deals
    • Biotech M&A – 2022 Deals
    • Biotech M&A – 2021 Deals
    • Biotech M&A – 2020 Deals
    • Biotech M&A – 2019 Deals
    • Biotech M&A – 2018 Deals
    • Clinical Holds – 2022
    • Direct Email
    • Real-Time Tweets
    • Real-Time Email Alerts
    • Team Positions
    • FAQ
  • All Reports – Premium Research
    • Daily Update
    • Research Reports
    • Charts & TA
    • Trade Reports
    • Tutorials
  • Forum – Exchange Insight

epanova

AMRN – Update on Amarin’s AMR101 as PDUFA date draws closer

Amarin Corp (NASDAQ: AMRN) released first quarter 2012 financial results and held a conference call on May 8, 2012. It is often hard to distinguish the signal from the noise when it comes to chatter about AMRN on Twitter and other venues, so we will try to objectively update where things stand as the July […]

By Andrew Goodwin May 22, 2012
In Chimera Blog

Press

© Copyright 2025 Chimera Research Group, Inc Disclaimer Disclosures Ethics Policy Privacy Policy Terms & Conditions

Log In

JoinLost Password?
  • Join Now
  • LoginClose